Investment Rating - The report maintains a "Buy" rating for the company [1][22]. Core Views - The sales of the product "Xihua Su" are experiencing rapid growth, and the company has secured its inclusion in the 2023 medical insurance catalog with a moderate price adjustment [2][22]. - The company is expected to see a significant increase in net profit over the next few years, driven by the strong competitive position of "Xihua Su" [22]. Financial Performance Summary - In 2023, the company achieved a revenue of 3,134.33 million yuan, representing a year-on-year growth of 22.69%. The net profit attributable to the parent company was 800.91 million yuan, up 116.58% year-on-year [7][21]. - The projected revenues for 2024, 2025, and 2026 are 3,762.48 million yuan, 4,631.73 million yuan, and 5,576.54 million yuan, respectively, with growth rates of 20.04%, 23.10%, and 20.40% [7][11]. - The net profit attributable to the parent company is expected to reach 1,092.76 million yuan in 2024, 1,404.32 million yuan in 2025, and 1,711.61 million yuan in 2026, with growth rates of 36.44%, 28.51%, and 21.88% respectively [7][11]. Product Sales Forecast - The sales forecast for "Xihua Su" is projected to be 2,816.5 million yuan in 2023, with a year-on-year growth of 25.1%. The expected sales for 2024, 2025, and 2026 are 3,379.8 million yuan, 4,157.1 million yuan, and 4,988.6 million yuan, with growth rates of 20%, 23%, and 20% respectively [11][12]. Profitability Metrics - The gross profit margin for 2023 is reported at 95.1%, with expectations to maintain this level in the coming years [7][11]. - The return on equity (ROE) is projected to be 26.01% in 2024, 26.04% in 2025, and 25.07% in 2026 [7][11].

财务报表分析和预测 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|--------|-------|-------------------------|-------|------------------------|-------|-------------------------|-------|-------| | 主要财务指标 | 2023A | 2024E | 2025E | 2026E | 利润表 ( 百万元 ) | 2023A | 2024E | 2025E | 2026E | | 每股指标 ( 元 ) | | | | | 营业总收入 | | 3,134 3,438 4,070 4,828 | | | | 每股收益 | | | 3.23 4.13 4.95 6.00 | | 营业成本 | | 155 189 224 241 | | | | 每股净资产 | | | 13.49 17.65 22.60 28.59 | | 毛利率 % | 95.1% | 94.5% | 94 ...

西藏诺迪康药业股份有限公司 证券代码：600211 证券简称：西藏药业 公告编号：2024-017 关于重大资产重组实施进展的公告 3、生产转换：依姆多生产转换共涉及 44 个国家和地区（其中不需要进行生产转换的 国家 5 个），海外市场已有 21 个国家和地区获批，获批的国家和地区由我公司委托的海外 生产商 Lab. ALCALA FARMA, S.L 供货，其余国家和地区正在办理中。中国市场已完成依姆 多上市许可持有人变更，并已委托有资质的生产厂生产依姆多产品；同时公司正在推进新 增原料药供应商和药品生产厂的相关工作，目前已向国家药品监督管理局药品审评中心递 交申请资料并得到受理。 公司将继续积极推进本次重大资产重组实施的相关工作，并按照相关规定及时披露实 施进展情况，敬请广大投资者关注公司在《中国证券报》《上海证券报》《证券时报》和上 海证券交易所网站（www.sse.com.cn）刊登的公司公告，注意投资风险。 特此公告。 西藏诺迪康药业股份有限公司 2024 年 3 月 30 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担 ...

证券简称：西藏药业 证券代码：600211 公告编号：2024-016 西藏诺迪康药业股份有限公司 获得产业扶持资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 获得补助金额：86,202,742 元 ● 对当期损益的影响：上述补助与收益相关，将计入当期损益，并对公司 2024 年度 损益产生积极影响。 2024 年 3 月 30 日 （一）获得补助概况 本公司及下属公司西藏诺迪康医药有限公司于 2024 年 3 月 29 日收到了山南市幸福家 园建设管理局拨付的产业发展扶持资金 86,202,742 元，占公司最近一期（2023 年度）经 审计归属于上市公司股东净利润的 10.76%。 （二）具体补助情况 单位：元 | 获得时间 | | | 发放单位 | 发放事由 | 补助依据 | 补助类型 | 补助金额 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2024 3 | 年 | 月 | 山南市幸 | 产业发展 | 银行回单（目 | | ...

Financial Performance - In 2024, the company aims to achieve total revenue of 3.4 billion yuan and control total costs within 2.4 billion yuan, targeting stable net profit growth [2]. - In 2023, the company's operating revenue increased by 22.69%, while the net profit attributable to shareholders grew by 116.56% [110]. - Basic earnings per share reached 3.23 CNY, a 116.78% increase compared to 1.49 CNY in 2022 [108]. - The company's operating revenue for 2023 was CNY 3,134,328,350.18, representing a year-on-year increase of 22.69% compared to CNY 2,554,609,066.22 in 2022 [1]. - Net profit attributable to shareholders for 2023 reached CNY 800,913,981.92, a significant increase of 116.56% from CNY 369,839,847.99 in 2022 [1]. - The net cash flow from operating activities was CNY 1,063,421,802.73, up 26.99% from CNY 837,377,038.26 in the previous year [1]. - The company's total assets at the end of 2023 were CNY 4,587,357,109.81, reflecting an 11.90% increase from CNY 4,099,694,705.46 at the end of 2022 [1]. - The company's sales expenses totaled 175,740.50 million RMB, accounting for 56.07% of operating income [78]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of CNY 1,063,421.80 million, up 26.99% year-on-year [153]. Dividend Distribution - The company plans to distribute a total cash dividend of RMB 480,751,477.58, which is 60.02% of the net profit attributable to shareholders for the full year 2023 [19]. - The cash dividend distribution includes a previously completed semi-annual cash dividend of RMB 298,021,287.29, which was RMB 12.02 per 10 shares (tax included) [21]. - The proposed cash dividend for this distribution is RMB 182,730,190.29 (tax included), equating to RMB 7.37 per 10 shares (tax included) [21]. - The total share capital will increase from 247,937,843 shares to 322,319,196 shares due to a capital reserve conversion of 3 shares for every 10 shares held [21]. Digital Transformation and Innovation - The company is focusing on digital transformation to integrate core business management modules, aiming for a standardized business blueprint and data standards [2]. - The company initiated a major digital construction project to enhance data management and operational efficiency [116]. - The company is actively pursuing the "Tibet Pharmaceutical Industry Integrity Action" digital construction project to enhance internal collaboration and resource sharing [2]. - The company is focused on expanding its market presence and developing new products and technologies [100]. - The company has developed a series of cardiovascular disease treatment products, enhancing its competitive edge in the market [151]. Research and Development - The company is conducting research on artificial cultivation of Tibetan medicinal materials, including the red景天 project, with plans to start snow rabbit seedling work in 2024 [3]. - The company has conducted research on artificial cultivation of endangered Tibetan medicinal materials, including Rhodiola rosea, to secure long-term resource advantages [151]. - The company is conducting research on the artificial cultivation of Rhodiola and other Tibetan medicinal herbs, improving survival rates and growth characteristics [169]. - The company has ongoing research projects, including the artificial cultivation of Rhodiola, currently in the technical research phase [199]. - Research and development expenses totaled CNY 17.39 million, accounting for 0.55% of operating revenue [186]. Corporate Governance - The company emphasizes strict compliance with corporate governance regulations and has established a robust internal management and control system [6]. - The board of directors consists of 9 members, including 3 independent directors, and held 5 meetings during the reporting period [6]. - The company has maintained a transparent information disclosure process, ensuring all shareholders have equal access to information [6]. - The company has not experienced any significant deviations from the regulatory requirements for corporate governance as per the China Securities Regulatory Commission [6]. - The independent audit of the company's 2023 financial report and internal control effectiveness was conducted by Sichuan Huaxin (Group) Accounting Firm, resulting in a standard unqualified opinion [24]. Environmental Responsibility - The company has not faced any environmental pollution incidents or administrative penalties during the reporting period [31]. - The company has implemented effective pollution control technologies and facilities, ensuring no exceedance of pollutant discharge limits in 2023 [31]. - The company established a robust internal control management system in compliance with legal regulations, enhancing decision-making and management efficiency [23]. - The wastewater treatment facility has a design capacity of 240m³/d, and the system has been operating stably since its establishment in 2002 [26]. - The company received a pollution discharge permit valid for five years from the Chengdu Ecological Environment Bureau on August 1, 2023 [27]. Social Responsibility - The company made a total donation of 88.16 million yuan for social responsibility projects, including 41.6 million yuan in cash and 46.56 million yuan in material donations [32]. - The company supported local economic development with cash donations of 40.77 million yuan and material donations of 164.28 million yuan to various villages in Tibet [34]. - The company increased local farmers' income by 117,500 yuan through a Tibetan medicinal herb planting project in 2023 [34]. - The company provided 18.16 million yuan worth of products as prizes for the Chengdu Senior Sports Association's events, benefiting over 580 participants [33]. - The company invested a total of 2.168 million RMB in poverty alleviation and rural revitalization projects, benefiting 1,609 people [52]. Market Performance - The sales revenue from the main business reached CNY 312,809.13 million, reflecting a year-on-year growth of 22.92%, with the product Xinhuasong accounting for 90.04% of total sales, increasing by 25.13% compared to the previous year [152]. - The production volume of Xinhuasong was 719.65 million units, with sales volume reaching 777.61 million units, marking a sales increase of 26.24% compared to the previous year [158]. - The revenue from the cardiovascular segment reached RMB 304.35 million, with a year-on-year increase of 23.76% [196]. - The gross margin for the cardiovascular segment is 95.89%, reflecting a slight increase of 0.70% compared to the previous year [196]. - The company has successfully promoted its product "Nodicon Capsule" through high-frequency exposure on CCTV channels, enhancing brand visibility [170].

| 四川华信(集团)会计师事务所 ｜地址:成都市洗面桥街 18号金茂礼都南 28楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028) 85560449 | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxcpa@163.net | 西藏诺迪康药业股份有限公司 2023 年度审计报告 川华信审(2024)第0006号 目录: 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ 1、审计报告 2、合并资产负债表 3、合并利润表 4、合并现金流量表 5、合并股东权益变动表 6、母公司资产负债表 7、母公司利润表 8、母公司现金流量表 9、母公司股东权益变动表 10、财务报表附注 西藏诺迪康药业股份有限公司 审计报告 审计报告 川华信审(2024)第 0006 号 西藏诺迪康药业股份有限公司全体股东: 一、审计意见 我们审计了西藏诺迪康药业股份有限公司（以下简称"贵公 司"）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 ...

证券代码：600211 证券简称：西藏药业 公告编号：2024-005 西藏诺迪康药业股份有限公司 第八届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、会议召开情况 公司第八届董事会第四次会议通知于 2024 年 3 月 15 日以电邮和微信的方式发出，会 议于 2024 年 3 月 25 日在成都市锦江区三色路 427 号以现场结合视频的方式召开。会议应 出席董事 9 名，实际参加会议表决的董事 9 名。会议由董事长陈达彬先生主持，公司监事 及高管列席了会议，会议的召开符合《公司法》及《公司章程》的有关规定。 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过该议案。 4、2023 年度利润分配预案： 二、会议审议情况 1、2023 年年度报告全文及摘要： 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过该议案。 公司 2023 年度财务会计报告已经董事会审计委员会 2024 年第一次会议审议通过。 详见公司同日发布的 2023 年年度报告全文及摘要。 2、2023 年度董事 ...

| 四川华信(集团)会计师事务所 地址:成都市洗面桥街 18 号金茂礼都南 28楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028) 85560449 | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxcpa@163.net | 西藏诺迪康药业股份有限公司 2023 年内部控制审计报告 川华信专(2024)第 0151 号 目录: 1、审计报告正文 2、西藏诺迪康药业股份有限公司 2023 年度内部控制评价报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn】 西藏诺迪康约业股份有限公司 内部控制审计报告 内部控制审计报告 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变 化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低，根据内部控制审 计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为,西藏药业于 2023 年 12 月 31 日按照《企业内部控制基本规范》 ...

西藏诺迪康药业股份有限公司 监事会议事规则 （2024 年 3 月修订） 第一章 总则 第一条 为完善公司法人治理结构，规范公司监事会运作，提高监事会的工 作效率，保证监事会依法行使职权，履行职责，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、其他有关法律、法规、规范性文件，以及《西藏 诺迪康药业股份有限公司章程》（以下简称"公司章程"）的规定，特制定《西 藏诺迪康药业股份有限公司监事会议事规则》（以下简称"本规则"）。 第二条 本规则适用于公司监事会定期会议和监事会临时会议。 第三条 出席监事会的人员应当遵守有关法律、法规、规范性文件、公司章 程以及本规则的规定，自觉维护会场秩序。 第二章 监事会的职权 第四条 公司设监事会，对公司的经营活动和董事、经理的经营管理行为进 行监督。 第五条 监事会对股东大会负责。 第六条 监事会的职权包括： （四）当董事、高级管理人员的行为损害公司的利益时，要求董事、高级管 理人员予以纠正； 1 （五）提议召开临时股东大会，在董事会不履行《公司法》规定的召集和主 持股东大会职责时召集和主持股东大会； （六）提议召开董事会临时会议； （七）向股东大会提出提案； （八 ...

西藏诺迪康药业股份有限公司 2023 年度独立董事述职报告 作为西藏诺迪康药业股份有限公司（以下简称"公司"）的独立董事，本人严格按照《公 司法》《证券法》《上市公司独立董事管理办法》《公司章程》等相关法律法规、制度的 规定和要求，忠实履行独立董事勤勉尽职的义务，独立、负责地行使职权，及时关注公司 的发展状况，积极出席公司2023年度召开的董事会等相关会议，对董事会的各项议案进行 认真审议，并对重大事项独立、客观地发表意见，充分发挥独立董事的独立作用，有效地 维护公司全体股东尤其是中小股东的合法权益。现将2023年度任职期间的履职情况汇报如 下: 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 二、独立董事履职情况 2023 年度，公司董事会进行了换届选举，本人被选举为公司第八届董事会独立董事， 本人均亲自出席任期内召开的所有会议，并认真审议各项议案，根据相关规定发表独立意 见，诚信勤勉，忠实尽责。 （一）出席董事会和股东大会会议情况 1 | 本年应参加 | 亲自 | 委托 | 缺席次数 | 是否连续两次 | 出席 | | --- | --- | --- | --- | --- | --- | ...